Evidence map›Paper›PMID 26937187›Full record

ReviewInternational journal of chronic obstructive pulmonary disease2016

Exacerbations of COPD.

Ian D Pavord, Paul W Jones, Pierre-Régis Burgel, Klaus F Rabe

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of chronic obstructive pulmonary disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 3 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis.International journal of chronic obstructive pulmonary disease · 2016
    Pooled it
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Ian D PavordRespiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Paul W JonesDivision of Clinical Science, St George's, University of London, London, UK.
Pierre-Régis BurgelDepartment of Respiratory Medicine, Cochin Hospital, University Paris Descartes, Sorbonne Paris Cité, Paris, France.
Klaus F RabeDepartment of Medicine, Christian Albrecht University, Kiel, Germany; LungenClinic, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany.
Christian-Albrechts-Universität zu Kiel · DEHôpital Cochin · FRUniversity of London · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as sustained worsening of a patient's condition beyond normal day-to-day variations that is acute in onset, and that may also require a change in medication and/or hospitalization. Exacerbations have a significant and prolonged impact on health status and outcomes, and negative effects on pulmonary function. A significant proportion of exacerbations are unreported and therefore left untreated, leading to a poorer prognosis than those treated. COPD exacerbations are heterogeneous, and various phenotypes have been proposed which differ in biologic basis, prognosis, and response to therapy. Identification of biomarkers could enable phenotype-driven approaches for the management and prevention of exacerbations. For example, several biomarkers of inflammation can help to identify exacerbations most likely to respond to oral corticosteroids and antibiotics, and patients with a frequent exacerbator phenotype, for whom preventative treatment is appropriate. Reducing the frequency of exacerbations would have a beneficial impact on patient outcomes and prognosis. Preventative strategies include modification of risk factors, treatment of comorbid conditions, the use of bronchodilator therapy with long-acting β2-agonists or long-acting muscarinic antagonists, and inhaled corticosteroids. A better understanding of the mechanisms underlying COPD exacerbations will help to optimize use of the currently available and new interventions for preventing and treating exacerbations.

Indexed as

Anti-Bacterial AgentsBiomarkersBronchodilator AgentsDisease ProgressionHumansLungPhenotypePredictive Value of TestsPulmonary Disease, Chronic ObstructiveRecovery of FunctionSeverity of Illness IndexTreatment OutcomeAnti-Bacterial AgentsBiomarkersBronchodilator AgentsbiomarkerbronchodilatorCOPDexacerbationphenotype

Identifiers

PMID26937187
PMCPMC4764047
OpenAlexW2286338494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.